International pricing index threatens cure to pandemic
Implementing an international pricing index (IPI) could mean hampering biopharmaceutical innovations that will save lives and help end the pandemic.
I hope our representatives in Congress will express their opposition to this dangerous policy.
In pursuing the most-favored-nation executive order that links domestic drug prices to foreign ones, President Trump's intentions are clear: bring down the high cost of American health care. However, the method of doing so can't be so easy, as it risks the valuable investments that biopharmaceutical companies have made in developing cures.
An IPI will make it much harder for American patients to access their medicine. When you've just been diagnosed with cancer, you don't have three months to wait for your treatment. IPI would also directly hurt innovation and research for groundbreaking drugs that could change the lives of those suffering from chronic conditions like multiple sclerosis, Alzheimer's, cancer and, of course, COVID-19.
This model threatens the very cure we're patiently waiting on to reverse our current course. I imagine there must be a solution to the high cost of health care and prescription medications that doesn't also threaten the innovation and access pipeline.
In the interest of saving American lives from COVID-19 and other chronic illnesses, I urge Oregon's lawmakers to work with their colleagues in Congress to devise an answer. And in the meantime, I hope they'll vocalize your opposition to this unwise policy.
Natalia Garzon is a resident of unincorporated Clackamas County, just south of Happy Valley city limits.
You count on us to stay informed and we depend on you to fund our efforts. Quality local journalism takes time and money. Please support us to protect the future of community journalism.